TABLE 3.
Pairwise comparisons of baseline and follow-up predicted mean HAMD and WHODAS scores
| Baseline | F | df | P | |
|---|---|---|---|---|
| HAMD | 0.35 | 2 | .703 | |
| Tele-PST | 23.54 (0.86) | |||
| In-person PST | 27.75 (0.83) | |||
| Care call | 24.64 (1.07) | |||
| WHODAS | 2.33 | 2 | .101 | |
| Tele-PST | 36.52 (1.16) | |||
| In-person PST | 34.21 (1.23) | |||
| Care call | 38.03 (1.28) | |||
| HAMD | 12-week follow-up | t | df | P |
|
|
||||
| Tele-PST vs. care call | 13.68 (1.00) vs. 18.93 (1.17) | −3.42 | 327.24 | .001 |
| In-person PST vs. care call | 14.08 (0.94) vs. 18.93 (1.17) | −3.24 | 327.05 | .001 |
| Tele-PST vs. in-person PST | 13.68 (1.00) vs. 14.08 (0.94) | −0.06 | 334.68 | .772 |
| WHODAS | ||||
| Tele-PST vs. care call | 29.72 (1.26) vs. 34.97 (1.48) | −2.72 | 270.07 | .007 |
| In-person PST vs. care call | 30.13 (1.19) vs. 34.97 (1.48) | −2.56 | 270.40 | .011 |
| Tele-PST vs. in-person PST | 29.72 (1.25) vs. 30.13 (1.19) | 0.24 | 278.41 | .809 |
| 24-week follow-up | t | df | P | |
| HAMD | ||||
|
|
||||
| Tele-PST vs. care call | 12.38 (0.85) vs. 17.21 (0.99) | −3.70 | 189.13 | <.001 |
| In-person PST vs. care call | 14.12 (0.80) vs. 17.21 (0.99) | −2.43 | 186.77 | .016 |
| Tele-PST vs. in-person PST | 12.38 (0.85) vs. 14.12 (0.80) | −1.49 | 194.20 | .138 |
| WHODAS | ||||
| Tele-PST vs. care call | 29.38 (1.12) vs. 34.15 (1.32) | −2.77 | 178.24 | .006 |
| In-person PST vs. care call | 30.60 (1.05) vs. 34.15 (1.32) | −2.11 | 176.72 | .036 |
| Tele-PST vs. in-person PST | 29.38 (1.12) vs. 30.60 (1.05) | −0.80 | 186.62 | .426 |
| 36-week follow-up | t | df | P | |
| HAMD | ||||
|
|
||||
| Tele-PST vs. care call | 11.08 (1.07) vs. 15.49 (1.23) | −2.72 | 363.21 | .007 |
| In-person PST vs. care call | 14.16 (0.99) vs. 15.49 (1.23) | −0.84 | 360.40 | .400 |
| Tele-PST vs. in-person PST | 11.08 (1.07) vs. 14.16 (0.99) | −2.11 | 374.10 | .035 |
| WHODAS | ||||
| Tele-PST vs. care call | 29.04 (1.32) vs. 33.33 (1.54) | −2.12 | 303.52 | .034 |
| In-person PST vs. care call | 31.07 (1.24) vs. 33.33 (1.54) | −1.15 | 300.37 | .251 |
| Tele-PST vs. in-person PST | 29.04 (1.32) vs. 31.07 (1.24) | −1.12 | 314.10 | .261 |
Parentheses denote standard error.
Note. 95% CI of the predicted HAMD means at 12-week follow-up: 11.72–15.65 for tele-PST group, 12.23–15.94 for in-person PST group, and 16.64–21.23 for care call group; at 24-week follow-up: 10.70–14.06 for tele-PST group, 12.55–15.69 for in-person PST group, and 15.26–19.16 for care call group; and at 36-week follow-up: 8.99–13.18 for tele-PST group, 12.21–16.11 for in-person PST group, and 13.08–17.90 for care call group.
95% CI of the predicted WHODAS means at 12-week follow-up: 27.25–32.19 for tele-PST group, 27.80–32.47 for in-person PST group, and 32.07–37.87 for care call group; at 24-week follow-up: 27.17–31.59 for tele-PST group, 28.53–32.68 for in-person PST group, and 31.57–36.74 for care call group; and at 36-week follow-up: 26.44–31.64 for tele-PST group, 28.64–33.50 for in-person PST group, and 30.32–36.35 for care call group.